anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an application of a ginkgo extract in preparation of an external preparation for treating osmidrosis. The ginkgo extract can be extracted from ginkgo leaves, fruits, exotesta, rhizome and other parts with ethanol, water, ethyl ether, petroleum ether and other organic solvents used as an extraction solvent by a chemical separation method. The osmidrosis comprises axillary region, foot, perineum and other part osmidrosis. The drug, cosmetic or disinfectant external preparation containing the ginkgo extract for treating osmidrosis contains 0.001-80% by weight of ginkgo extract and pharmaceutically common external preparation media or acceptable carriers; and the preparation is any one pharmaceutically external dosage form. Local stimulation experiment study shows that the external preparation provided by the invention is safe, and has no skin stimulus, irritability and other side effects. Clinical trial result shows that the external preparation provided by the invention has a significant treatment action on osmidrosis with the effective rate up to 100%, is safe to use and has no side effects.
The present disclosure relates to the technical field of pharmaceutical preparations, and in particular to a zolpidem double-layered osmotic pump controlled release tablet and a preparation method thereof. The controlled release tablet uses a double-layered osmotic pump controlled release technology. An upper layer is a drug layer containing zolpidem or a salt thereof, and a lower layer is a push layer containing a push agent and an osmotically active substance. Poly(ethylene oxide) is used as a main push agent in the drug layer and the push layer, a lactose and sodium chloride compound is used as an osmotically active substance in the drug layer, and sodium chloride is used as an osmotically active substance in the push layer. The appropriate push agent and osmotically active substance are selected such that the prepared drug is linearly released within six hours and the cumulative release amount is greater than 80%. The defect that excessively quick, excessively slow or inconsistent release rate of existing drugs causes unbalanced drug effects and damages human body functions is overcome.
Cervical cancer remains a significant health burden in China, characterized by high incidence and mortality rates, which are exacerbated by low Human Papillomavirus (HPV) vaccination coverage, leading to substantial loss of productivity, emotional suffering, and family strain. Understanding factors that influence HPV awareness and knowledge is crucial for developing effective educational strategies. This cross-sectional study, conducted from September to October 2022, involved 2,679 college students from various educational institutions in Jiangsu Province, China. Data were collected via an online questionnaire covering demographics, HPV knowledge, and vaccination behaviors. Statistical analyses, including Chi-square tests and multifactorial logistic regression, were used to identify factors influencing HPV knowledge. The study revealed that while over 90% of students correctly identified HPV's transmission and risks, significant knowledge gaps and misconceptions persist, particularly regarding HPV's association with HIV/AIDS and its treatment. Factors significantly associated with better HPV knowledge included age (22-24 years), female gender, being a medical major, being in a relationship, familiarity with HPV, and participation in sexual education programs. Despite a high willingness to receive the HPV vaccine (91.64%), actual vaccination rates remained low. These findings suggest that while Chinese college students were generally aware of HPV, targeted educational interventions are essential to address knowledge gaps and promote HPV vaccination effectively.
PURPOSE: We investigated the impact of anesthesia mode on perinatal outcomes in patients with placenta accreta spectrum (PAS) undergoing cesarean delivery and identified factors associated with adverse perinatal events.
METHODS: The multicenter retrospective analysis was conducted in patients with PAS who delivered at three medical centers. Patients were classified according to whether they received general anesthesia (GA) or neuraxial anesthesia (NA). We compared the basic clinical characteristics of patients in the pre-propensity score matching (PSM) and post-PSM cohorts and identified factors associated with a high risk of adverse maternal outcomes.
RESULTS: This study included a total of 425 patients, with 307 (72.2%) in the GA group and 118 (27.8%) in the NA group. After PSM, 162 patients were identified for analysis. In the post-matched cohort, the NA group exhibited shorter total operation time (P = 0.030) and postoperative length of hospital stay (P = 0.037). Additionally, the NA group experienced lower intraoperative blood loss (P < 0.001) and received fewer units of transfused packed red blood cells (PRBC) (P < 0.001). Multivariate logistic regression analysis indicated that GA (P < 0.001), emergency cesarean delivery (P = 0.010), vascular lacunae within the placenta (P < 0.001), hypervascularity of uterine-placental margin (P = 0.002), hypervascularity of the cervix (P = 0.014), and balloon placement in the abdominal aorta (P < 0.001) were associated with a high risk of adverse maternal events.
CONCLUSION: In comparison to GA, cesarean delivery with NA in PAS patients appears to be associated with reduced intraoperative blood loss, PRBC transfusion, operating duration, and postoperative hospital stay.
The slow released anticancer injection containing estrogen receptor antagonist consists of slow released microsphere and solvent. The slow released microsphere includes effective anticancer component and slow releasing supplementary material, and the solvent contains suspending agent. The effective anticancer component is estrogen receptor antagonist selected from Fullvesrant, Eximestane, etc or the composition of estrogen receptor antagonist and estrogen receptor antagonist synergist selected from taxane, alkylating agent and/or plant alkaloid. The slow releasing supplementary material is selected from difatty acid-sebacic acid copolymer, EVAc, polylactic acid, etc. The suspending agent is carboxymethyl cellulose sodium, etc. and has viscosity of 100-3000 cp at 20-30 deg.c. The slow released microsphere may be also prepared into slow released implanting agent for lowering systemic toxic reaction, raising local concentration optionally and rising chemotherapeutic and/or radiotherapeutic effect.
PURPOSE OF REVIEW: Spinal cord stimulation (SCS) is an increasingly utilized therapy for the treatment of neuropathic pain conditions. Though minimally invasive and reversable, there are several important device-related complications that physicians should be aware of before offering this therapy to patients. The aim of this review is to synthesize recent studies in device-related SCS complications pertaining to cylindrical lead implantation and to discuss etiologies, symptoms and presentations, diagnostic evaluation, clinical implications, and treatment options.
RECENT FINDINGS: Device-related complications are more common than biologic complications. Device-related complications covered in this review include lead migration, lead fracture, lead disconnection, generator failure, loss of charge, generator flipping, hardware related pain, and paresthesia intolerance. The use of SCS continues to be an effective option for neuropathic pain conditions. Consideration of complications prior to moving forward with SCS trials and implantation is a vital part of patient management and device selection. Knowledge of these complications can provide physicians and other healthcare professionals the ability to maximize patient outcomes.
The method is used in the pharmaceutical industry and hashigh yield and purity. The method is effected when a thiocarbamidesuspension heated to boiling temperature (78-82°C) in anhydrousethyl alcohol for 0.5 to 2.0 h hot solution of2-diethylaminoethylchloridehydrochloride is added to anhydrousethyl alcohol. The process of isothioronic salt synthesis occursat temperature range from 78-80°C for 4-6 h. The crystalline massproduced is cooled, filtered and dried. The isothioronic salt isdissolved in water, heated to 60-80°C and a solution of sodiumhydroxide is added to the reaction mass for 10-20 min. It isadditionally agitated for 15-30 min at this temperature, an upperlayer of 2-diethylaminoethanethiol is separated, a specificquantity of sodium chloride is added for desalination and it isextracted by organic solvent, prefelably toluene. The extractionsolution is subjected to presaturation with hydrogen chloride toclearing, where crystals of side admixtures are produced pollutingthe end product. The crystals are separated by filtration and theclear solutin is saturated by hydrogen chloride to pH 1 to 2. Thecystals of the diethylaminoethanethiohydrochloride are filteredand dried.1 claim
PURPOSE:To obtain the titled composition containing an antimicrobial zeolite, alcohol and propellant. CONSTITUTION:An antimicrobial zeolite [zeolite in which an ion capable of carrying out ion exchange is partially or wholly substituted by an antimicrobial metal ion (ion of silver, copper or zinc)] and propellant (e.g. flon gas such as trichlorofluoromethane or liquefied petroleum gas such as propane or butane) are incorporated to provide the aimed antimicrobial composition for spray. The composition contains suitably 1-10%, preferably 2-6% antimicrobial zeolite, 29-49%, preferably 35-40% alcohol and 50-70%, preferably 55-65% propellant. The spray is used as spray for deordorizing of shoes, deordorizing of body smell after sport, deodorant, deordorizing of garbage and antimicroorganism. Further, the spray can also be used for purpose providing antimicrobial properties on the surface of various kinds of resins, papers, woods, metals, etc.
PROBLEM TO BE SOLVED: To develop a tooth decay preventive agent derived from a material from which neither smell nor teste becomes problem.SOLUTION: The tooth decay preventive agent includes the algae extract of Codinaceae algae. In the tooth decay preventive agent, the Algae may belong to the Codium. The Algae may belong to at least one kind of species of the Codium selected from the group consisting of Codium fragile, Codium tomentosum, Codium minus, Codium spongiosum, Codium subtubulosum, Codium intricatum and Codium cylindricum. In the tooth decay preventive agent, the algae extract may be obtained by extracting pulverized algae with an aqueous solution. In the tooth decay preventive agent, the algae extract may be lectin coupled with a sugar chain competing with GalNAc. A pharmaceutical composition, a food composition, a dentifrice and a mouth rinse contain the tooth decay preventive agent.
Donepezil hydrochloride is a reversible inhibitor of the enzyme acetylcholinesterase, known chemically as (±)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1 H-inden-1-one hydrochloride. Donepezil hydrochloride is commonly referred to in the pharmacological literature as E2020. It has an empirical formula of C 24H 29NO 3HCl and a molecular weight of 415.96. Donepezil hydrochloride is a white to off-white powder and is freely soluble in chloroform, soluble in water and in glacial acetic acid, slightly soluble in ethanol and in acetonitrile and practically insoluble in ethyl acetate and in n-hexane. 

  


Donepezil hydrochloride orally disintegrating tablets, USP are available for oral administration. Each donepezil hydrochloride orally disintegrating tablet, USP contains 5 mg or 10 mg of donepezil hydrochloride. Inactive ingredients are microcrystalline cellulose, mannitol, sucralose, sodium chloride, peppermint flavor, crospovidone, colloidal silicon dioxide, magnesium stearate. Additionally, the 10 mg tablet contains ferric oxide (yellow) as a coloring agent.
Each CO-OP session will last 60 minutes and subjects will complete one session per week over the course of 10 weeks. All sessions will be delivered remotely via the Zoom platform.
A medical device management system includes a plurality of medical devices communicating with a local area network. A local network appliance forwards device data gathered from the medical devices to a cloud based service that processes and organizes the device data. The cloud based service may also be in communication with a sales database, an ERP system, a manufacturing database, and/or other databases. Users may request device data from the cloud based service using a conventional web browser. The device data may include location data, usage data, repair data, etc. In some cases, device data may come from a variety of sources and the cloud based service collates the multi-source data together into a set of records that form a digital replica of the actual medical device.
PURPOSE:To improve the accuracy of diagnosing the cancer serum by using the glycoprotein antigen of a specific isoelectric point which exists in at least the serum of a hepatoma patient and conjugates specifically with an NM 17 mouse monoclonal antigen as a cancer marker. CONSTITUTION:The glycoprotein antigen of 5.6 to 5.9 isoelectric point which is the glycoprotein antigen conjugating specifically with the NM 17 mouse monoconal antibody (antibody produced in the hybridoma of commission number 10280 of the bacteria commissioned to BIKOKEN) and exhibits 70000 to 1200000 mol. wt. in the serum of the cancer patient has the excellent specificness to the cancer and has a high sensitivity without degrading the positive rate even at the min. hepatoma (<= 2cm tumor diameter). This glycoprotein antigen exists in at least the serum of the hepatoma patient. The glycoprotein antigen hardly exists in the serum of a healthy person or is slight even if this antigen exists therein. The enzyme immunoassay (EIA) kit using the NM 17 mouse monoclonal antibody to this glycoprotein antigen is usable as a useful cancer serum dianostic drug for diagnosing the cancer serum of the hepatoma, etc.
Stiffness measurement using shear wave propagation velocity has been the most common non-invasive method for liver fibrosis assessment. The velocity is captured through a trace recorded by transient ultrasonographic elastography, with the slope indicating the velocity of the wave. However, due to various factors such as noise and shear wave attenuation, detecting shear wave trajectory on wave propagation maps is a challenging task. In this work, we made the first attempt to use deep learning methods for shear wave trajectory detection on wave propagation maps. Specifically, we adopted five deep learning models in this task and evaluated them by using a well-acknowledged metric based on EA-Angular-Score (EAA) and task-specific metric based on Young s-Score (Ys) in the line-detection field. Furthermore, we proposed an end-to-end framework based on a Transformer and Hough transform, named Transformer-enhanced Hough Transform (TEHT). It took a wave propagation map as input image and directly output the slope of the shear wave trajectory. The framework extracts multi-scale local features from wave propagation maps, employs a deformable attention mechanism for feature fusion, identifies the target line using the Hough transform's voting mechanism, and calculates the contribution of each scale through channel attention. Wave propagation maps from 68 patients were utilized in this study, with manual annotation performed by a rater who was trained as a radiologist, serving as the reference value. The evaluation revealed that the SLNet model exhibited F-measure of EA and Ys values as 40.33 % and 40.72 %, respectively, while the TEHT model showed F-measure of EA and Ys values as 80.96 % and 98.00 %, respectively. TEHT yielded significantly better performance than other deep learning models. Moreover, TEHT demonstrated strong concordance with the gold standard, yielding R2 values of 0.967 and 0.968 for velocity and liver stiffness, respectively. The present study therefore suggests the application of the TEHT model for assessing liver fibrosis owing to its superiority among the five deep learning models.
Disclosed is an edible film ingestible from the mouth cavity of a living body into the body.  The edible film is formed of a laminate comprising a plurality of layers.  The layers include an anti-adhesion layer, which prevents the edible film from adhering to the inner wall of the mouth cavity through dissolution in water.  The laminate has two surface layers constituting the surfaces of the laminate.  The anti-adhesion layer is disposed as at least one of the surface layers of the laminate.  This edible film is a film that is less likely to adhere to the inner wall of the mouth cavity and, if adhered, can be easily peeled off.
Patients, who consent to participate in the study, will randomly receive either succinylcholine or rocuronium by utilizing the Dixon's up and down technique. For patient safety, the first dose of either agent will be defined by the anesthesiologist providing care, and subsequent doses will be incrementally increased or decreased by 10% based on the assessment of a psychiatrist blinded to dose, who uses a dichotomous scale to assess the quality of the ECT (acceptable and not acceptable). The investigators will switch to the second compound as soon as the patient has received one neuromuscular blocking agent dose that resulted in 'acceptable muscle relaxation', and another dose that resulted in 'unacceptable' conditions'.

Acceleromyography will be used for monitoring neuromuscular transmission. Following induction of general anesthesia, the TOF-Watch SX will be calibrated (mode 1, 50 mA), and train-of-four (TOF) stimulation (every 15 seconds) will be initiated and maintained until recovery of the T1 to 100% baseline. Non-invasive blood pressure, heart rate, peripheral oxygen saturation (SpO2), and time to recovery of spontaneous breathing will be measured during the procedure. In addition the investigators will measure stimulation parameters used to initiate ECT, as well as the duration of seizure as well as the entire procedure time.
The effect of renal impairment on silodosin pharmacokinetics was evaluated in a single dose study of six male patients with moderate renal impairment and seven male subjects with normal renal function. Plasma concentrations of silodosin were approximately three times higher in subjects with moderate renal impairment compared with subjects with normal renal function.

RAPAFLO should be reduced to 4 mg per day in patients with moderate renal impairment. Exercise caution and monitor patients for adverse events.

RAPAFLO has not been studied in patients with severe renal impairment. RAPAFLO is contraindicated in patients with severe renal impairment [see Contraindications (4), Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].
Microfluidics technologies stand as the latest sperm selection methodology for ICSI. Increasingly, publications show novel and ingenious microfluidics strategies to integrate sperm biomimicry during in vitro sperm selection while simplifying the IVF workflow. Microfluidics are time-efficient methods which reduce the risks associated with handling, gamete mix-up and ROS production. However, microfluidics devices are costly and likely to fail to select motile sperm in dispermic samples. Aiming to outline the application of microfluidics in ART, the investigators conceived a lab-on-a-chip approach for sperm selection by In-Situ rheotaxis handmade microfluidics of fluidic walls. This microfluidics system allows selecting sperm for ICSI in the same ICSI-dish. Thus, from a microvolume of the raw semen sample, only using microfluidics, disregarding centrifugation, washing, plasticware, other cells, products or materials, and using the same culture medium needed to prepare the rest of the ICSI plate.

A previous proof-of-concept study showed that this methodology efficiently selected suitable sperm for ICSI. The investigators also demonstrated that the microfluidic protocol effectively separates at least 20 progressive spermatozoa in less than 15 minutes in a clean microdroplet, free of any remaining seminal plasma. A subsequent non-inferiority study showed that the microfluidic method performs as well as density gradient centrifugation to achieve ICSI outcomes such as fertilization and day-5 blastocyst formation rate, proving that In-Situ handmade rheotaxis microfluidics of fluidic walls are also effective in supporting pre-implantation embryonic development in vitro.
<P>PROBLEM TO BE SOLVED: To provide a screening method and a proper evaluation system for developing a drug having cell-death inducing activity or proliferation suppressing activity on cancer cells or developing an assistant drug for recovering sensitivity of known anticancer agent resistant strains.  <P>SOLUTION: Cancer cells are seminated at a low density and cultured to form a colony. A test drug is added, and a cell image is captured with time and compared with a result attained without adding the test drug to calculate the proliferation rate of the cell and cell-death inducing rate of the test drug on each colony. The average values of the proliferation rate of the cell and the cell-death inducing rate of the whole cell mass are calculated from the values of each colony together with variation coefficient of both data for each cell, and these values are calibrated by a control to evaluate the efficacy as an anticancer agent or as an assistant drug of known anticancer agents. Influence of the drug on normal cells is evaluated by performing contrast experiment on normal cells in the screening of the anticancer agent and on a system added with only the assistant drug in the case of screening the assistant drug.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Methods and compositions for controlling gene expression are disclosed. In accordance with the present invention, compositions and methods are provided for modulating the expression of a gene of interest. Specifically, nucleic acid molecules encoding a polypeptide comprising a ONA binding domain and a looping factor are provided. The DNA binding domain and the looping factor may be linked through a covalent bond or an amino acid linker. In a particular embodiment, the DNA binding domain comprises a zinc finger polypeptide or a transcription activator-like effector polypeptide. The DNA binding domain may be designed to specifically bind a target sequence in the promoter of a gene of interest to modulate its expression.
This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks. This study will consist of a Screening Visit, a 52 week Treatment Period, and a Follow-up Visit. Informed consent will be obtained prior to performing any study-specific procedures. All patients will have a Screening Visit, which can be performed anytime within 14 days prior to the first dose of study drug, to confirm eligibility.

Clinical laboratory tests, electrocardiograms (ECGs), vital signs, adverse events, and concomitant medications will be monitored throughout the study. Blood samples for inflammatory biomarkers will be collected from all patients prior to dialysis on Day 1 and periodically until the End of Treatment or Early Termination Visit. Blood samples will also be collected periodically for clinical laboratory tests.
During the course of the 18 week study this arm will receive no intervention. Participants will be encouraged to maintain their daily schedules.Following the completion of the study the participants will be offered eight yoga sessions over a one month period.